Clinical Trial Update: Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of LLG783 in patients with peripheral artery disease and intermittent claudication has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Claudication
• Peripheral Artery Disease

Drugs mentioned

• LLG783

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Peripheral Artery Disease (PAD); Intermittent Claudication | Phase 2 | Status: COMPLETED | Results posted: 2020-01-31